Advent Life Sciences — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Cytedcytedhealth.comSeries B · Aug 2025 · $44M
Cyted Health develops diagnostics for earlier and more accurate detection of esophageal disease, including its EndoSign capsule sponge cell collection device and molecular diagnostics, intended for clinicians screening for conditions such as Barrett's Esophagus and esophageal cancer.
BiotechHealthtechMedical Devices
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.